

EFFECTIVE DATE: 10|06|2009

POLICY LAST UPDATED: 09|05|2017

OVERVIEW

Radioembolization (RE), referred to as selective internal radiation therapy or “SIRT” in older literature has been developed for the treatment of unresectable primary and secondary liver cancer.

MEDICAL CRITERIA

Radioembolization may be considered medically necessary as a treatment for any of the following:

- Primary hepatocellular carcinoma that is unresectable and limited to the liver.
- In primary hepatocellular carcinoma as a bridge to liver transplantation.
- Hepatic metastases from neuroendocrine tumors (carcinoid and noncarcinoid) with diffuse and symptomatic disease when systemic therapy has failed to control symptoms.
- Unresectable hepatic metastases from colorectal carcinoma melanoma (ocular or cutaneous), or breast cancer that are both progressive and diffuse, in patients with liver-dominant disease who are refractory to chemotherapy or are not candidates for chemotherapy.
- Primary intrahepatic cholangiocarcinoma in patients with unresectable tumors.

PRIOR AUTHORIZATION

Prior authorization is required for BlueCHiP for Medicare members and recommended for Commercial products.

POLICY STATEMENT

BlueCHiP for Medicare and Commercial Products

Radioembolization is considered medically necessary when the medical criteria have been met.

Radioembolization is considered not medically necessary for all other indications.

COVERAGE

Benefits may vary between groups and contracts. Please refer to the appropriate Benefit Booklet, Evidence of Coverage, or Subscriber Agreement for the applicable radiology benefits.

BACKGROUND

RADIOEMBOLIZATION

The use of external beam radiotherapy and the application of more advanced radiotherapy approaches (e.g., intensity-modulated radiotherapy) may be of limited use in patients with diffuse, multiple lesions due to the low tolerance of normal liver to radiation compared with the higher doses of radiation needed to kill the tumor.

Various nonsurgical ablative techniques have been investigated that seek to cure or palliate unresectable hepatic tumors by improving locoregional control. These techniques rely on extreme temperature changes (cryosurgery or radiofrequency ablation [RFA]), particle and wave physics (microwave or laser ablation), or arterial embolization therapy including chemoembolization, bland embolization, or Radioembolization.

Radioembolization (RE), referred to as selective internal radiation therapy (SIRT) in older literature, is the intra-arterial delivery of small beads (microspheres) impregnated with yttrium-90 via the hepatic artery. The

microspheres, which become permanently embedded, are delivered to tumor preferentially to normal liver, because the hepatic circulation is uniquely organized, whereby tumors greater than 0.5 cm rely on the hepatic artery for blood supply while normal liver is primarily perfused via the portal vein.

Yttrium-90 is a pure beta-emitter with a relatively limited effective range and short half-life that helps focus the radiation and minimize its spread. Candidates for Radioembolization are initially examined by hepatic angiogram to identify and map the hepatic arterial system. At that time, a mixture of technetium 99-labeled albumin particles is delivered via the hepatic artery to simulate microspheres. Single photon emission computed tomography imaging is used to detect possible shunting of the albumin particles into gastrointestinal or pulmonary vasculature.

Currently, 2 commercial forms of yttrium-90 microspheres are available: a glass sphere (TheraSphere) and a resin sphere (SIR-Spheres). Noncommercial forms are mostly used outside the United States. While the commercial products use the same radioisotope (yttrium 90) and have the same target dose (100 Gray), they differ in microsphere size profile, base material (ie, resin vs glass), and size of commercially available doses. The physical characteristics of the active and inactive ingredients affect the flow of microspheres during injection, their retention at the tumor site, spread outside the therapeutic target region, and dosimetry calculations. The Food and Drug Administration (FDA) granted premarket approval of SIR-Spheres for use in combination with 5-fluorouridine chemotherapy by hepatic arterial infusion to treat unresectable hepatic metastases from colorectal cancer. In contrast, TheraSphere was approved by humanitarian device exemption for use as monotherapy to treat unresectable hepatocellular carcinoma (HCC). In 2007, this humanitarian device exemption was expanded to include patients with HCC who have partial or branch portal vein thrombosis. For these reasons, results obtained with one product do not necessarily apply to another commercial (or noncommercial) products.

CARCINOMAS TREATED WITH RADIOEMBOLIZATION

Unresectable Primary HCC

Most patients with HCC present with unresectable disease and treatment options are limited secondary to the chemoresistance of HCC and the intolerance of normal liver parenchyma to tumoricidal radiation doses. Results of two randomized controlled trials have shown a survival benefit for transarterial chemoembolization (TACE) therapy compared with supportive care in patients with unresectable HCC. One study randomized patients to TACE, transarterial embolization (TAE), or supportive care. One-year survival rates for TACE, TAE, and supportive care were 82%, 75%, and 63%, respectively; 2-year survival rates were 63%, 50%, and 27%, respectively. Targeted therapies have been investigated for HCC. For example, sorafenib was associated with improved overall survival in a randomized phase 3 trial with 602 patients.

Unresectable Intrahepatic Cholangiocarcinoma

Cholangiocarcinomas are tumors that arise from the epithelium of the bile duct and are separated into intrahepatic and extrahepatic types. Intrahepatic cholangiocarcinomas appear in the hepatic parenchyma and are also known as peripheral cholangiocarcinomas. Resection is the only treatment with the potential for cure, and 5-year survival rates have been in the range of 20% to 43 %. Patients with unresectable disease may select among fluoropyrimidine-based or gemcitabine-based chemotherapy, fluoropyridimine chemoradiation or best supportive care.

Unresectable Metastatic Colorectal Cancer

Fifty to sixty percent of patients with colorectal cancer will develop metastases, either synchronously or metachronously. Select patients with liver-only metastases that are surgically resectable can be cured, with some reports showing 5-year survival rates exceeding 50%. The emphasis of treating these patients with potentially curable disease is on complete removal of all tumors with negative surgical margins. Most patients diagnosed with metastatic colorectal disease are initially classified as having unresectable disease. In some patients with metastatic disease limited to the liver, preoperative chemotherapy is sometimes used to downsize the metastases to convert the metastatic lesions to a resectable status (conversion chemotherapy).

In patients with unresectable disease, the primary treatment goal is palliative, with a survival benefit shown in both second- and third-line systemic chemotherapy. Recent advances in chemotherapy, including oxaliplatin, irinotecan, and targeted antibodies like cetuximab, have doubled the median survival in this population from less than one year to more than 2 years. Palliative chemotherapy using combined systemic and hepatic arterial infusion may increase disease-free intervals for patients with unresectable hepatic metastases from colorectal cancer.

Radiofrequency ablation has been found inferior to resection in local recurrence rates and five-year overall survival rates; further, it is generally reserved for patients with potentially resectable disease that cannot be completely resected due to patient comorbidities, location of metastases (ie, adjacent to a major vessel), or an estimate of inadequate liver reserve following resection. Radiofrequency ablation is recommended when the goal of complete resection with curative. The role of local (liver-directed) therapy (including radioembolization, chemoembolization, and conformal radiotherapy) in debulking unresectable metastatic disease remains controversial.

Unresectable Metastatic Neuroendocrine Tumors

Neuroendocrine tumors are an uncommon, heterogeneous group of mostly slow-growing, hormone-secreting malignancies, with an average patient age of 60 years. Primary neuroendocrine tumors vary in location, but most are either carcinoids (which most commonly arise in the mid gut) or pancreatic islet cells. Carcinoid tumors, particularly if they metastasize to the liver, can result in excessive vasoactive amine secretion including serotonin and are commonly associated with the carcinoid syndrome (diarrhea, flush, bronchoconstriction, right valvular heart failure).

Although they are considered to be indolent tumors, at the time of diagnosis, up to 75% of patients have liver metastases, and with metastases to the liver, 5-year survival rates are less than 20%. Surgical resection of the metastases is considered the only curative option; however, less than 10% of patients are eligible for resection, as most patients have diffuse, multiple lesions.

Conventional therapy is largely considered to be palliative supportive care to control, eradicate, or debulk hepatic metastases, often to palliate carcinoid syndrome or local pain from liver capsular stretching. Therapies for unresectable metastatic neuroendocrine tumors include medical (somatostatin analogs like octreotide), systemic chemotherapy, ablation (radiofrequency or cryotherapy), TAE or TACE, or radiation. Although patients often achieve symptom relief with octreotide, the disease eventually becomes refractory, with a median duration of symptom relief of approximately 13 months, with no known effect on survival. Systemic chemotherapy for these tumors has revealed a few things: (1) that modest response rates are of limited duration; (2) that it is better for pancreatic neuroendocrine tumors than carcinoids; and (3) that it is frequently associated with significant toxicity. Chemoembolization has shown response rates of nearly 80%, but the effect is of short duration, and a survival benefit has not been demonstrated.

Miscellaneous Metastatic Tumors

Case reports have been published on the use of radioembolization in many other types of cancer with hepatic metastases, including breast, melanoma, head and neck (including parotid gland), pancreaticobiliary, anal, thymic, thyroid, endometrial, lung, kidney, gastric, small bowel, esophageal, ovarian, cervical, prostatic, bladder, and for sarcoma and lymphoma.

CODING

BlueCHiP for Medicare and Commercial Products

There are no specific CPT codes describing radioembolization therapy. Providers should file using the unlisted CPT code:

77399

RELATED POLICIES

None

PUBLISHED

Provider Update, November 2017
Provider Update, October 2016
Provider Update, January 2016
Provider Update, February 2015
Provider Update, January 2014
Provider Update, December 2012
Provider Update, March 2011

REFERENCES

1. Llovet JM, Real MI, Montana X et al. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomized controlled trial. *Lancet* 2002; 359(9319):1734-9.
2. Lo CM, Ngan H, Tso WK et al. Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. *Hepatology* 2002; 35(5):1164-71.
3. Llovet J, Ricci S, Mazzaferro V et al. Sorafenib improves survival in advanced Hepatocellular Carcinoma (HCC): Results of a Phase III randomized placebo-controlled trial (SHARP trial). *J Clin Oncol* 2007; 25(18S):LBA1.
4. National Cancer Network NCCN Clinical Practice Guidelines in Oncology: Hepatobiliary Cancers. Version 2.2015. http://www.nccn.org/professionals/physician_gls/pdf/hepatobiliary.pdf. Accessed April, 2015
5. Tice J. Selective internal radiation therapy or radioembolization for inoperable liver metastases from colorectal cancer California Technology Assessment Forum 2010 http://www.ctaf.org/sites/default/files/assessments/1150_file_SIRT_RE_final_W2.pdf. Accessed April, 2015.
6. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology. Colon Cancer. Version 2.2016. http://www.nccn.org/professionals/physician_gls/PDF/colon.pdf. Accessed July 18, 2016
7. King J, Quinn R, Glenn DM et al. Radioembolization with selective internal radiation microspheres for neuroendocrine liver metastases. *Cancer* 2008; 113(5):921-9.
8. Kennedy AS, Salem R. Radioembolization (yttrium-90 microspheres) for primary and metastatic hepatic malignancies. *Cancer J* 2010; 16(2):163-75.
9. Salem R, Lewandowski RJ, Mulcahy MF et al. Radioembolization for hepatocellular carcinoma using yttrium-90 microspheres: a comprehensive report of long-term outcomes. *Gastroenterology* 2010; 138(1):52-64.
10. Tao R, Li X, Ran R, et al. A mixed analysis comparing nine minimally invasive surgeries for unresectable hepatocellular carcinoma patients. *Oncotarget*. Jan 17 2017;8(3):5460-5473. PMID 27705924
11. Lobo L, Yakoub D, Picado O, et al. Unresectable hepatocellular carcinoma: radioembolization versus chemoembolization: a systematic review and meta-analysis. *Cardiovasc Intervent Radiol*. Nov 2016;39(11):1580-1588. PMID 27586657

12. Lewandowski RJ, Kulik LM, Riaz A et al. A comparative analysis of transarterial downstaging for hepatocellular carcinoma: chemoembolization versus radioembolization. *Am J Transplant* 2009; 9(8):1920-8.
13. Hoffmann RT, Paprottka PM, Schon A et al. Transarterial hepatic yttrium-90 radioembolization in patients with unresectable intrahepatic cholangiocarcinoma: factors associated with prolonged survival. *Cardiovasc Intervent Radiol* 2012; 35(1):105-16.
14. Kolligs FT, Bilbao JI, Jakobs T, et al. Pilot randomized trial of selective internal radiation therapy vs. chemoembolization in unresectable hepatocellular carcinoma. *Liver Int.* Nov 29 2014. PMID 25443863
15. Pitton MB, Kloeckner R, Ruckes C, et al. Randomized Comparison of Selective Internal Radiotherapy (SIRT) Versus Drug-Eluting Bead Transarterial Chemoembolization (DEB-TACE) for the Treatment of Hepatocellular Carcinoma. *Cardiovasc Intervent Radiol.* Nov 7 2014. PMID 25373796
16. El Fouly A, Ertle J, El Dorry A, et al. In intermediate stage hepatocellular carcinoma: radioembolization with yttrium 90 or chemoembolization? *Liver Int.* Feb 2015; 35(2):627-635. PMID 25040497
15. Gramenzi A, Golfieri R, Mosconi C, et al. Yttrium-90 radioembolization vs sorafenib for intermediate-locally advanced hepatocellular carcinoma: a cohort study with propensity score analysis. *Liver Int.* Apr 22 2014. PMID 24750853
17. Soydal C, Arslan MF, Kucuk ON, et al. Comparison of survival, safety, and efficacy after transarterial chemoembolization and radioembolization of Barcelona Clinic Liver Cancer stage B-C hepatocellular cancer patients. *Nucl Med Commun.* Jun 2016;37(6):646-649. PMID 26905317
18. Oladeru OT, Miccio JA, Yang J, et al. Conformal external beam radiation or selective internal radiation therapy-a comparison of treatment outcomes for hepatocellular carcinoma. *J Gastrointest Oncol.* Jun 2016;7(3):433-440. PMID 27284477
19. Salem R, Gordon AC, Mouli S, et al. Y90 Radioembolization significantly prolongs time to progression compared with chemoembolization in patients with hepatocellular carcinoma. *Gastroenterology.* Dec 2016;151(6):1155-1163 e1152. PMID 27575820
20. Jia Z, Paz-Fumagalli R, Frey G, et al. Resin-based Yttrium-90 microspheres for unresectable and failed first-line chemotherapy intrahepatic cholangiocarcinoma: preliminary results. *J Cancer Res Clin Oncol.* Mar 2017;143(3):481-489. PMID 27826686

CLICK THE ENVELOPE ICON BELOW TO SUBMIT COMMENTS

This medical policy is made available to you for informational purposes only. It is not a guarantee of payment or a substitute for your medical judgment in the treatment of your patients. Benefits and eligibility are determined by the member's subscriber agreement or member certificate and/or the employer agreement, and those documents will supersede the provisions of this medical policy. For information on member-specific benefits, call the provider call center. If you provide services to a member which are determined to not be medically necessary (or in some cases medically necessary services which are non-covered benefits), you may not charge the member for the services unless you have informed the member and they have agreed in writing in advance to continue with the treatment at their own expense. Please refer to your participation agreement(s) for the applicable provisions. This policy is current at the time of publication; however, medical practices, technology, and knowledge are constantly changing. BCBSRI reserves the right to review and revise this policy for any reason and at any time, with or without notice. Blue Cross & Blue Shield of Rhode Island is an independent licensee of the Blue Cross and Blue Shield Association.

